OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Thursday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Down 13.2 %

Shares of NASDAQ:OPGN opened at $1.65 on Thursday. The company has a 50 day moving average of $1.92 and a 200 day moving average of $3.01. OpGen has a 12 month low of $1.61 and a 12 month high of $9.90.

OpGen (NASDAQ:OPGN) last released its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. The business had revenue of $0.03 million for the quarter.

Institutional Investors Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new stake in OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent filing with the SEC. 2.68% of the stock is currently owned by institutional investors.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.